Advertisements

Rexahn Pharmaceuticals Inc. (RNN) Stock Quote

Detailed Quote for Rexahn Pharmaceuticals Inc. (RNN)
$ 0.4962   -0.0138 (-2.71%) Volume: 4.34m 4:02 PM EDT Mar 28, 2017
After Hours:  $ 0.49   -0.0062 (-1.25%) Volume: 13.19k 6:10 PM EDT Mar 28, 2017
Today 5d 1m 3m 1y more
Last Price
0.4962
Change $
0.0138
Change %
2.71%
Tick
  
Bid
0.49
Bid Size
900
Ask
0.51
Ask Size
4,000
Open
0.5105
High
0.5248
Low
0.462
Prev Close
0.51
Last Trade
4:02
Volume
4.34m
52 Wk Hi
0.561999976
52 Wk Low
0.127000004
Market Cap
117.82m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
237,443,785
EPS (TTM)
-0.039999999
PE Ratio
N/A
Exchange
NYSE MKT
News and Media for Rexahn Pharmaceuticals Inc. (RNN)
Sector News | Topic News
News for Rexahn Pharmaceuticals Inc. (RNN)
Tue, Mar 28, 2017
9:41 AM BioDelivery Sciences International and Rexahn Pharmaceuticals See Share Values Rise Slightly - Accesswire
Thu, Mar 16, 2017
9:31 AM Trade Volume Can Speak a Lot About Momentum of a Stock - Accesswire
Mon, Feb 27, 2017
9:10 AM Rexahn Pharmaceuticals reports FY results - SeekingAlpha
9:01 AM Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update - GlobeNewswire
Thu, Feb 23, 2017
9:00 AM Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin(TM) in Patients with Metastatic Triple Negative Breast Cancer - GlobeNewswire
Fri, Jan 20, 2017
9:00 AM Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium - GlobeNewswire
Tue, Jan 03, 2017
9:01 AM Rexahn Pharmaceuticals to Present at Biotech Showcase(TM) 2017 - GlobeNewswire
Mon, Nov 07, 2016
2:07 PM Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update - GlobeNewswire
Mon, Oct 31, 2016
9:01 AM Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 - A Cancer Cell Specific Anticancer Agent - GlobeNewswire
Wed, Oct 26, 2016
9:03 AM Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors - GlobeNewswire
Tue, Oct 11, 2016
5:21 PM Rexahn's Tumor-Targeted Therapy Shows Efficacy In Incurable Pancreatic Cancer - SeekingAlpha
Mon, Oct 10, 2016
7:00 AM Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin(TM) Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress - GlobeNewswire
Tue, Oct 04, 2016
9:02 AM Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin(TM) Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress - GlobeNewswire
Wed, Sep 14, 2016
9:03 AM Rexahn Announces $6 Million Registered Direct Offering - GlobeNewswire
Mon, Sep 12, 2016
9:02 AM Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer - GlobeNewswire
Wed, Sep 07, 2016
9:02 AM Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw\u00A0 Global Investment Conference on September 12, 2016 - GlobeNewswire
Mon, Aug 08, 2016
9:01 AM Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial and Operational Results - GlobeNewswire
Mon, Jul 11, 2016
9:02 AM Rexahn Pharmaceuticals Strengthens Leadership Team - GlobeNewswire
Mon, Jun 06, 2016
9:02 AM Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical Oncology Annual Meeting - GlobeNewswire
Mon, May 23, 2016
9:36 AM Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting - GlobeNewswire
More News for RNN >>

Tags for Rexahn Pharmaceuticals Inc.

Research stocks or mutual funds related to Rexahn Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to RNN. The keywords below have been associated to RNN by either user submission or electronic means.

Drugs Healthcare Common Stock Pharmaceutical Preparation Manufacturing (325412) Pharmaceutical Preparations (2834)